fourth quarter earn preview portola
biodeliveri scienc favorit earn cycl
report outlin thought biopharma fourth-quart earn cycl
set commenc next week exhibit follow broad sector weak
fourth quarter nasdaq biotechnolog index nbi amex biotechnolog index
btk respect sector fundament remain intact larg
industry-friendli fda ramp activ off-set continu discuss around
drug price pressur complet biotech ipo fourth quarter quarter-
over-quart still total deal rais billion despit mani compani schedul
list opt due poor market condit on-going govern shutdown
expect backlog qualiti biotech seek public list drive ipo market
thaw billion mega-acquisit bristol-my squibb/
celgen combin smaller deal loxo oncolog although
seen partial recoveri fourth quarter marketwid sell-off still see re-rat
sector provid opportun high convict name
provid addit commentari sector company-specif thought
fourth-quart earn cycl coverag univers report compani
yet pre-announce earn earli januari view portola biodeliveri
scienc hold potenti beat consensu estim recent investor event portola
disclos continu expans andexxa new hospit addit hospit
sent first shipment andexxa addit hospit reorder andexxa
first time fourth quarter creat potenti opportun exceed consensu
estim million quarterli sale also increas estim biodeliveri
scienc belbuca script grew impress quarter although note
gross-to-net discount key metric compani report
clear insight trend slightli reduc estim
collegium head fourth-quart earn cycl given modest prescript
growth quarter maintain estim compani
issu guidanc earli januari also reduc estim aclariss eskata
challeng third quarter sale given in-licens rhofad
fourth quarter believ integr two product like near-term focu
commerci compani share perform like driven
busi clinic catalyst calendar includ six meaning studi read
year would focu phase ii topic program alopecia areata first
half year phase wart studi second half year
provid detail discuss compani later report appendix
section also includ updat model compani review
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
tabl content
biopharmaceut index perform valuat overview page
stagnant biopharma environ turn tesaro loxo celgen acquisit page
twelv biopharma fourth quarter ipo file volum hinder govern re-open page
fourth quarter privat ventur biopharma fund dip macro condit still histor strong page
list append model page
industri question issu
billion acquisit celgen bristol-my squibb enough stimul biotech market
trigger big pharma mobil cash reserv leverag balanc sheet bolster pipelin
besid shikeda merger second half lack-lust smidcap public biotech
larg sell discount level suspect window close
drug-pric pressur trump administr continu weigh industri
propos price test medicar part reimburs
see presid trump head human servic hh depart azar
eas drug-pric commentari anytim soon understand trial price
model initi basket inject therapi cover medicar part reimburs plan
discuss demonstr project
gene cell therapi gener transform clinic data commerci product sticker shock
price potenti need value-bas reimburs model hinder profit access
ground-break therapeut
fda clearli made cell gene therapi approv prioriti compromis quality-
control aav autologous/allogen cell therapi consid sheer amount product
requir treat even rare diseas see capit invest partnership manufactur critic
space see note fda commission cber director statement reinforc agenc bullish view
innov cell gene therapi highlight biotech focu day cell gene therapi
manufactur expand keep clinic timelin
biopharmaceut index perform valuat overview
strong first half biopharma indic revers gain second half exhibit
point nasdaq biotechnolog index nbi amex biotechnolog index btk
respect fourth quarter like due initi consid biotech-specif sell-off pre-midterm elect
manifest marketwid sell event composit respect
note drg index least hit remain healthcar equiti space
sought safe-harbor de-risk tradit large-cap revenue-gener pharma oppos risk-on development-
stage biotech name note biotech market somewhat recov troublesom fourth-quart sell-off
nbi btk respect year-to-d outperform gener market measur
 index appreci time period believ biotechnolog perform
driven number factor includ increas earn corpor tax reform continu specul base
recent up-tick activ back lacklust second half metric medic advanc cutting-edg
compani gene cell therapi space still biotech market fulli recov fourth quarter
neg market sentiment continu see weak space prime opportun posit mani
name trade rel discount fundament chang
exhibit follow page summar biotechnolog pharmaceut compani earn revenu
valuat metric assum comp group see large-cap biotechnolog compani pharmaceut compani
trade histor reason averag time consensu earn per share respect compar
time multipl report third quarter earn preview believ quarter-over-
quarter declin price-to-earnings multipl pharmaceut compani sector reflect generalist investor transit
healthcar equiti fourth quarter yet opt back space
tickerpric y/i amex jone industri performanceaccur factsetexhibit performanceq/q quarter-over-quart ytd year-to-d y/i year-over-year william blair
biotechnolog reflect calculationr number consid outlier includ averag calcul sourc factset exhibit per share valuat compar biotechnolog pharmaceut companiesconsensu william blair
biotechnolog factset biotechnologyexhibit revenueev/revenu multiplesconsensu revenueev/revenu multiplesrevenu valuat compar biotechnolog pharmaceut compani william blair
stagnant biopharma environ turn tesaro loxo celgen
summar exhibit note fourth quarter akin third previous quiet period
biopharma transact discuss ventur fund earlier-stag privat compani remain
histor strong despit public market sell-off smidcap public compani continu command negoti
posit attract valuat large-cap pharma whole yet mobil cash reserv bolster
last year corpor tax reform result cash repatri believ recent biotech sell-off volatil
around midterm elect bought mani valuat premium back within acquisit territori continu
view opportunist window market continu recov big pharma refil pipelin next-gener
product believ earli mover glaxosmithklin bristol-my squibb acquir tesaro loxo celgen
respect repres open potenti window predict player activ valuat
smidcap remain discount high still would like see underli volum deal boost
throughout rather singl big-ticket takeout bristol-my acquir celgen billion takeda
complet billion acquisit shire would indic underli organ activ biopharma
space recov posit strength turn drive investor confid
fourth-quart biopharma reach transact total billion increas billion biopharma
 valu execut third quarter note without billion acquisit tesaro
glaxosmithklin fourth-quart transact valu would lowest five year still deal volum
rel consist histor averag total biopharma compani acquisit stake purchas busi
unit buy fourth quarter list pertin transact exhibit biggest deal quarter belong
glaxosmithklin billion acquisit tesaro oncolog space follow novartiss take-over
endocyt million obvious first quarter seen spike activ bristol-my squibb
announc billion take-over deal celgen scoop loxo oncolog billion billion
shikeda mega-merg takeda shire also complet januari deal announc second quarter
sequenti pass global anti-trust committe sharehold vote approv back first quarter
spike sentiment continu see takeout potenti compani aclari
vike therapeut spark other coverag base rational hold
clinic de-risk best-in-class asset bolster large-cap pharma pipelin mani trade valuat discount
peer anticip biopharma stori alway major theme despit macro pressur note mani
compani larger deal potenti yet make major move includ allergan merck
biocenturyiq william blair compani llcexhibit announc biopharma transactionstot amount rais billion total amount rais billion number transactionsbuyersellerd announcedd typeminimum deal valueasset stagebristol-my squibbcelgenethursday januari lillyloxo oncologymonday januari nordiskstaten biotechnologymonday decemb lillyhydra biosciencesfriday decemb antagonistsndpreclinicalamag perospher thursday decemb iibausch health companiessynergi wednesday decemb purchasetrul plecanatid decemb iiglaxosmithklinetesaromonday decemb novemb ii/iiiedg biotechnologymonday novemb iiituesday novemb ii/iiituesday novemb iiicumberland theravancetuesday novemb purchasevibativ wednesday octob octob allerganmonday octob neurosciencestuesday octob acquisitionndphas iinot includ nyse issuanc biocenturyiq compani reportsavenu ciplafourth-quart ytd biopharma bolt-on transact summaryexhibit mereo biopharma grouparsani enlivex bioblast pharma william blair
twelv biopharma fourth-quart ipo file volum hinder govern
 ipo market brought privat biotech compani public sector collect rais all-tim high
billion despit govern shutdown poor market condit fourth quarter forc mani compani
queue withhold issuanc privat ventur fund see page continu strong strong
environ could see issuanc begin increas govern shutdown run cours still see
strong tailwind industri includ favor regulatori environ fda approv novel drug
ultim believ buyer high-qual biotech ipo award perform exclud neg
sentiment associ fourth-quart list expect high-qual compani continu see buyer public
exhibit summar biotech ipo market perform past sever quarter year-to-d analysi
limit nyse issuanc note biotech ipo volum depress quarter-over-quart
list fourth quarter rais billion averag offer size million compar prior
quarter still respect consid histor averag volatil around novemb midterm elect
poor market sentiment prevent mani compani list note figur inflat
million ipo unicorn led post-money valuat billion despit midterm elect
neg market sentiment fourth quarter see ipo trend remain strong consid mani
compani still queue await govern open offic continu believ biotech
innov aliv well fuel privat ventur fund eventu growth public entiti
provid list complet biotech ipo fourth quarter current year-to-d exhibit note
aforement allogen post largest ipo offer million million respect
particip ipo biotech compani list exhibit would yield averag return post-first-day
trade perform rang appreci allogen depreci furthermor
analyz year-end perform biotech ipo complet fourth quarter mean roughli depreci stock
perform ipo offer price realiz accord evalu pharma continu view market
hold posit sentiment ipo prior quarter pend govern reopen
biocenturi bciq note includ nyse issuancesexhibit ipo histor ipostot amount rais million total amount rais million number ipo william blair
china pharmaceut januari group decemb decemb decemb novemb octob cell octob octob octob octob octob octob octob biocenturi bciq note includ nyse issuancesfirst day close priceperformancetickerexhibit ytd complet iposcompani nameamount raisedd completedstatu financingpost-money valuationoff price william blair
fourth quarter privat ventur biopharma fund dip macro condit still
alongsid ipo market privat ventur fund somewhat depress quarter-over-quart still remain
histor high fourth quarter billion privat capit invest biopharma deal bring
yearli total deal volum suppli billion privat capit compar favor billion rais
exhibit similar third quarter mani compani success rais greater million round
deal magnitud restrict later seri round shown even spread top rais complet
fourth quarter exhibit largest round fund belong relay cerevel million seri
million term sheet respect sign fourth quarter key fund area drug develop includ
discoveri platform neurolog oncolog gene therapi note even first week januari
alreadi seen biotech privat ventur deal total million expect ventur fund remain strong throughout
earli stage innov continu flow pipe activ potenti increas due less expens
valuat public market alongsid ipo window re-open collect suppli exit opportun privat
evalu pharma william blair compani llcexhibit quarterli biopharma ventur ventur transactionstot amount rais million total amount rais million number ventur transact william blair
section highlight specif second-quart earn outlook compani biotechnolog
pharmaceut coverag univers break section three group larg cap mid-cap small cap order
compani alphabet ticker within group provid top-level perform exhibit append
up-to-d earn model highlight compani end report within compani
discuss also provid top question manag go earn result
companyamount rais million seriesroundlocationdatespacerelay discoverycerevel discoveryaspyrian monoclonalsaimmun therapynd disclos pipe privat invest public equitysourc evalu pharma global privat ventur fund deal million large-cap perform base william blair comparison groupsdata correct factset exhibit ytdfi mid small-cap perform summari william blair
updat estim prior compani fourth quarter earn call schedul januari
maintain fourth-quart humira sale estim billion line consensu estim
billion slightli increas fourth-quart imbruvica sale estim million previou estim
million greater consensu million also lower fourth-quart hcv sale estim
million due increas price competit gilead previou estim million similar consensu
estim million lower fourth-quart top-lin revenu billion billion
consensu billion maintain full year top-lin revenu billion consensu
billion slightli lower fourth-quart non-gaap ep estim consensu
estim full-year non-gaap ep estim previous
consensu estim exhibit also bull eye govern crack price practic
pressur share near futur view despit pressur govern rais price
five drug start includ humira look forward manag comment
continu pressur note neg sentiment continu put pressur share
write rova-t major setback pipelin next month good number late-stag
pipelin catalyst commerci launch multipl new blockbust franchis label extens due on-going
disappoint stemcentrx acquisit punctuat recent decis stop enrol phase
taho trial rova-t rovalpituzumab tesirin treatment second-lin sclc compani decis record
roughli billion impair charg billion intang asset acquisit compani look
rebuild investor confid continu execut orilissa elagolix approv endometriosis-associ pain
juli launch third quarter potenti approv orilissa treatment heavi menstrual bleed
hmb associ uterin fibroid uf could occur approv risankizumab psoriasi consid
low risk event upadacitinib rheumatoid arthriti anticip upadacitinib compani
plan submit new drug applic nda compris data five complet phase select studi fda
fourth quarter believ upadacitinib pois becom prefer agent among oral jak inhibitor
addit label expans new exist product on-going particular late-stag monotherapi
combin studi imbruvica frontlin pancreat cancer frontlin mantl cell lymphoma second-lin follicular
lymphoma third-lin multipl myeloma pivot studi venclexta non-hodgkin lymphoma type
question manag
current polit environ affect humira franchis compani strategi
write rova-t affect top line beyond pipelin candid stemcentryx
updat thought upadacitinib posit given filgotinib phase data show rel clean safeti
phase studi zanubrutinib ibrutinib waldenstrom read strategi
superior demonstr
believ hcv franchis reach equilibrium gilead strategi move forward
upsid row market
updat cf collabor galapago
maintain estim allergan remain within full year guidanc issu last quarter ahead
compani report financi result tuesday januari market open top line estim total
fourth-quart revenu billion slightli consensu billion bottom line see
non-gaap net incom billion per share narrow consensu billion per share
report basi estim net loss million per share compar consensu loss
million per share
earn review call expect manag comment potenti impact statu botox competit
revanc compani continu late-stag develop neutoxin aesthet
therapeut indic also expect manag provid addit clariti potenti path forward esmya
issu abbvi elagolix affect uterin fibroid market approv indic addit
expect commentari compani ubrogep file abort treatment episod migrain expect first
quarter enrol cadenc on-going pivot atogep trial assess efficaci oral anti-cgrp receptor
therapi prevent set franchis posit biohaven noject migrain therapi
platform also expect major depress made signific focu compani pipelin discuss given recent
posit data axsom earli januari jansen esketamin current nda review compani
expect top-lin short-term treatment data phase trial rapastinel adjunct therapi major depress
disord first half see allergan high-qual pharmaceut compani prefer maintain market
perform rate growth stori becom clearer beyond divestitur women health infecti diseas still
progress debt paydown
question manag
rational file nda mg mg mg ubrogep dose episod migrain
mg dose success complet two pivot trial
fda requir non-inferior trial re-formul abicipar product open-label mapl trial
wet patient suffic patient suffici demonstr intra-ocular pressur safeti
product truli differenti current market therapi given readi adopt treat extend
wb william blair compani estim exhibit inc estim revis dollar million except ep stock price capit billionmarket performallergan plc william blair
plan recent acquir fast-act neurotoxin bonti becom accret
botox franchis later year product posit market separ product entir
provid enrol updat phase trial atogep prevent migrain
expect would efficaci compar cgrp inject market
report fourth-quart full-year earn tuesday januari market close believ investor
focus sale recent launch aimovig seen strong prescript growth sinc launch
second quarter neulasta given recent launch biosimilar competit addit believ investor
listen commentari recent launch lower price repatha determin uptak drug improv
also look forward commentari launch amjevita europ biosimilar humira opportun
europ consid signific given estim billion annual sale brand product howev initi
feedback signific price discount given multipl biosimilar launch octob therefor maintain
temper expect potenti sale amjevita time
slightli modifi estim outlin exhibit continu assess competit landscap
approv therapi oper expens addit ad estim sale biosimilar avastin
herceptin increas total biosimilar revenu estim
lastli ad estim first time estim ep
question manag
initi sign stabil neulasta onpro busi face first approv
timelin data read-out earli stage program includ bite car-t therapi
on-going focu remain busi develop capit alloc particularli follow recent
acquisit tesaro celgen loxo oncolog
report fourth-quart full-year earn tuesday januari market open investor
continu monitor spinraza sale continu anticip robust growth particularli outsid unit state
howev increas competit field includ anticip approv gene therapi year oral
administ risdiplam temper long-term expect spinraza estim peak sale spinraza
unit state reach billion peak sale come outsid unit state
pressur long-term prospect spinraza place greater focu sourc revenu growth name
alzheim franchis aducanumab undoubtedli remain key focu ahead phase result
anticip earli given lack late stage pipelin asset outsid alzheim stroke anticip
manag face pressur investor acquir late-stag asset busi develop
made slight adjust financi estim well publish estim first time
summar exhibit
amgen report william blair compani estim exhibit inc guidanc estim dollar million except ep stock price capit billionoutperformbiogen inc william blair
question manag
initi feedback commerci launch imraldi biosimilar humira europ manag see
market place evolv multipl approv biosimilar
kind eros spinraza sale unit state manag anticip gene therapi approv
sma confid patient eventu receiv therapi
registr pathway look like target therapi al
tweak fourth-quart earn out-year estim biomarin result model rebuild
correct legaci assumpt summar exhibit estim top-lin fourth-quart product revenu
million slightli consensu million suggest investor focu launch metric
recent fda-approv palynziq phenylketonuria million estim line consensu
product complet second full quarter sale decemb total patient palynziq
reimburs compris patient previous enrol clinic studi new kuvan nave patient addit
remain patient palynziq current complet eight-week induct phase wait reimburs
place daili mainten dose schedul new patient referr actual kuvan switch
patient recal kuvan exclus expect laps third quarter manag made
commerci prioriti convert mani kuvan user palynziq prior loss exclus event also expect
compani potenti strategi submit regulatori file request acceler approv valrox hemophilia
major focu earn call ahead expect decis second half
wb biogen report william blair compani estim exhibit inc guidanc estim dollar million except ep stock price capit billionoutperformbiomarin pharmaceut inc william blair
question manag
go-to-market strategi palynziq approv europ chmp deliv opinion first
quarter market dynam specialist center logist significantli differ unit
move part drive decis whether file valrox acceler approv second half
packag look potenti regulatori concern patient on-going clinic
trial yet dose commerci product bridg studi look like long would
take
make commentari recent fda meet hemophilia therapi multipl clinic
expert state factor level need low near-norm level prevent bleed event
normal factor viii level actual requir efficaci issu discuss payer
bristol-my middl signific transform follow announc acquisit celgen per share
cash billion one share bristol-my stock worth billion current share price combin compani
assum deal closur third quarter combin revenu billion significantli expand
pipelin although bristol-my share recov sinc initi declin follow announc on-going
patent litig around celgen signific revenu product revlimid like keep compress multipl
share combin compani ahead greater clariti around gener entri pipelin potenti recent investor
also assess potenti acquir make bid bristol-my derail celgen deal
long rumor potenti bid believ likelihood acquir bristol-my low point
given recoveri share price premium like requir bristol-myerss share warrant consider
wb incom william blair compani estim exhibit inc estim revis dollar million except ep stock price capit billionoutperformbristol-my squibb compani william blair
addit celgen acquisit investor continu focu clinic read out opdivo cancer
immunotherapi pipelin expect nonsmall-cel lung cancer nsclc much discuss indic
phase read out part part anticip
question manag
bristol-my anticip divest asset celgen follow acquisit
compani integr cell therapi busi exist infrastructur commit
continu innov keep competit
novel drug combin may pursu near term combin pipelin product
updat model estim gilead reflect recent product trend ahead compani fourth quarter
earn call schedul februari hcv franchis base bloomberg intellig prescript
data decreas fourth-quart vosevi sale estim million million estim
total hcv franchis revenu fourth quarter million slightli previou estim million
versu consensu estim million hiv franchis base script trend higher growth antivir
market biktarvi anticip increas biktarvi fourth-quart sale estim million
million greater consensu estim million also lower complera/eviplera fourth-
quarter sale estim million million previous rais viread fourth-quart sale
estim million million previous fourth-quart total hiv antivir estim
increas project billion sale billion previous line consensu billion
follow product estim chang project fourth-quart top-lin revenu billion billion
previous line consensu billion estim full year top-lin revenu billion
billion previous line consensu billion fourth-quart non-gaap ep estim
slightli previou estim consensu full year non-gaap ep estim
previou estim consensu exhibit
key data catalyst gilead share phase readout selonsertib nash earli
two phase studi evalu selonsertib monotherapi bridg fibrosi
compens cirrhosi respect sterllar studi began screen patient first quarter goal
enrol patient trial co-primari endpoint studi percent patient achiev least
one stage improv fibrosi score without worsen nash week event-fre surviv week
secondari endpoint includ proport patient nash resolut without worsen fibrosi variou time
point proport patient progress cirrhosi week current estim probabl success
billion peak sale selonsertib note phase ii studi selonsertib patient
fibrosi regress demonstr dose-depend manner small number patient selonertib
studi patient prior phase studi
question manag
hcv franchis stabil comment hcv competit mavyret plan combat
launch china go
posit filgotinib ra given data date compar jak inhibitor
gener thought nash strategi selonsertib fail
updat commerci strategi label expans yescarta technolog product need acquir
maintain leadership posit allogen cell therapi advanc solid tumor
potenti area focu potenti celgen acquisit bristol-my squibb
affect gilead thought mega-acquisit
thought hbv space
prior fourth quarter full year earn announc maintain fourth-quart estim
jakafi million compar consensu estim million reflect growth third quarter
slightli lower full year jakafi revenu estim billion billion
previous consensu billion continu project fourth-quart total revenu million
consensu estim million discrep revenu due recognit million innov mileston
payment manag expect occur first quarter believ analyst ascrib mileston
fourth quarter caus consensu revenu estim high full year revenu estim billion
line consensu billion fourth-quart non-gaap ep estim line consensu full
year non-gaap ep estim slightli consensu full year non-gaap ep estim
previous line consensu exhibit
major catalyst includ potenti acceler approv jakafi steroid-refractori acut gvhd phase readout
studi jakafi steroid-refractori acut chronic gvhd phase readout
itacitinib steroid-nav acut chronic gvhd updat pivot phase ii studi pemigatinib
second line cholangiocarcinoma subsequ nda file well phase ii readout jakafi cream vitiligo partner eli
lilli expect report phase top-lin data baricitinib atop dermat first half impact
share well
question manag
updat life cycl extens jakafi franchis
expect olumi atop dermat phase market outlook
wb william blair compani estim exhibit inc estim revis dollar million except ep stock price capit billionmarket performincyt corpor william blair
estim durat treatment jakafi itacitinib respect gvhd indic
updat thought increas activ start year incyt posit either side
lead compani fourth quarter earn lower fourth-quart symdeko sale estim
million million previous consensu estim million also increas
third-quart orkambi sale estim million million previous consensu estim
million result increas fourth-quart total revenu million million
previous consensu million full year revenu estim remain billion line
consensu billion fourth-quart non-gaap ep estim previous
consensu full year non-gaap ep estim previous consensu
key catalyst first quarter top-lin data second tripl combo phase studi expect posit
interim data vertex phase tripl combin trial symdeko late reproduc phase ii
percent predict forc expiratori volum one second increas improv
homozyg patient improv het/min patient interim data second
phase trial symdeko expect first quarter vertex intend choos better regimen vx-
potenti regulatori submiss expect tripl combo regimen address cf
popul market earli meanwhil competit tripl combo data expect proteostasi first
quarter could impact vertex share proteostasi potenti corrector doubl combo pti-
led maximum mean absolut improv percentag point seemingli better symdeko
tripl combo data amplifi expect come week compet tripl
combo achiev least improv homozyg het/min patient
accompani mmol/l drop sweat chlorid believ view competit vertex expect
vertex share come current level competit fail meet mark see sizabl upsid vertex
share lead earli phase readout monopol cf market immedi futur
wb william blair compani estim exhibit corporationestim revis dollar million except ep stock price capit billionmarket performvertex pharmaceut incorpor william blair
question manag
criteria choos tripl combo file nda
expect tripl combo competit proteostasi
updat detail overview pipelin what next
mid-cap compani market cap billion billion
base script report symphoni health observ quarter-over-quart increas total prescript
cabometyx end increas cabometyx sale million million third quarter
cabometyx benefit million inventori build howev manag indic even favor
inventori trend week hand stood lower end histor rang therefor believ inventori
advers affect cabometyx revenu quarter result adjust fourth-quart ep estim
per share compar per share previous full year ep increas
question manag
drove rapid advanc cabometyx plu tecentriq combin phase studi
hepatocellular carcinoma
comment flow patient advanc opdivo plu yervoy frontlin renal cell carcinoma
academ physician adopt cabometyx evolv time continu halo effect
provid refin time data releas sever phase ib cohort
wb william blair compani estim exhibit pharmaceut incorporatedestim revis dollar million except ep stock price capit billionoutperformexelixi inc william blair
ahead sarepta fourth quarter financi report adjust exondi revenu estim base
compani preannounc unaudit sale figur earli januari compani announc fourth quarter exondi
revenu million bring yearli sale million remain within full-year million
million guidanc rang continu place dystrophin skip product duchenn muscular dystrophi
dmd trajectori becom one success rare-diseas drug launch histori preliminari report
quarterli revenu figur came estim million slightli consensu million
bottom line anticip fourth-quart gaap-report net loss million per share includ
million expens relat lysogen acquisit may explain varianc consensu net loss
million per share adjust model accord prereleas top-lin revenu maintain
oper expens outer-year estim summar exhibit
although european eteplirsen approv look delay consid neg chmp review decis expect
issu dwarf expect on-going gene therapi program call expect manag provid
commentari dmd microdystrophin limb girdl muscular dystrophi -sarcoglycan myonexu trial alongsid
develop plan gene therapi asset recent acquir lacerta lysogen given data
microdystrophin gene therapi program date see note call follow-up phase i/iia data highlight
unpreced function benefit patient seen dmd potenti neuromuscular disord
pair compani rna platform continu view sarepta core mid-cap hold sector maintain
question manag
updat product capabl partner brammer paragon commercial-grad gene
view competit landscap pomp diseas gene therapi program place
expect casimersen-induc dystrophin express similar golodirsen current nda
review chang oligom affin exon-skip effici would affect express muscl biopsi
enrol dose progress cohort pivot microdystrophin gene therapi trial
immunogen concern dose develop overtim may limit microdystrophin express
previou exelixi report william blair compani estim exhibit inc guidanc estim dollar million except oper oper expens stock price capit billionoutperformsarepta therapeut inc william blair
small-cap compani market cap less billion
reduc fourth-quart revenu estim eskata w/w hydrogen peroxid fda-approv
therapi seborrh keratos commerci launch may reduc estim
million million reflect commentari hear clinician requir intens train
properli appli topic product new fourth-quart total revenu estim million includ
million servic revenu consensu million bottom line estim net loss million
per share compar slightli greater loss consensu million per share although
still believ market eskata see launch requir train origin anticip
reduc full-year revenu estim million million product exhibit
call expect commentari newli acquir rhofad product allergan complet decemb
integr eskata also expect larg focu review open-label data topic select
janus-associ kinas inhibitor treatment alopecia areata aa vitiligo ahead expect
top-lin data fulli enrol patient-strong phase ii vehicle-control trial patchi aa two on-going open-
label trial approxim hair regrowth respons rate six month treatment observ see note
final pictur want topic jak inhibit show hair regrowth compar nice
respons rate report investigator-l compound pharmaci topic jak inhibitor trial see note jakd
opportun alopecia areata jak inhibitor set becom blockbust class dermatolog share
significantli under-perform howev current valuat level million market cap million
cash believ share perform improv focu move compani commerci effort
eskata rhofad back toward compani pipelin provid catalyst-rich import
readout jak inhibitor franchis well two pivot trial w/w treatment common
wb exondi incom william blair compani estim exhibit inc estim revis dollar million except ep stock price capit millionoutperformaclari inc william blair
question manag
earli experi rhofad on-board see eskata sale forc secur addit account would
otherwis abl get foot door
averag much time dermatologist new eskata dedic applic train
given launch eskata date view opportun w/w common wart
jak inhibitor franchis
maintain estim fourth-quart adama financi compani pre-releas gocvori revenu earli
januari prompt us review model see note on-going gocovri market traction reflect solid quarter pivot
inroad data expect could support label expans compani report million quarter-over-
quarter fourth-quart sale paid script quarter-over-quart gocovri extend releas
amantadin therapi treatment levodopa-induc dyskinesia lid associ parkinson diseas pd
commerci launch januari figur beat estim million consensu million
bring inaugur yearli sale number million paid prescript manag aim
doubl volum previous adjust model reflect preliminari report expect
doubl script volum approxim doubl gocovri revenu year-over-year continu reflect modest
penetr rate gross-to-net discount averag within previous guid manag
bottom line estim quarterli net loss million loss per share compar consensu net loss
million per share
given pre-releas expect focu call compani plan achiev doubl gocovri
prescrib clinician patient educ consid impress product profil
enrol cadenc pivot inroad phase trial multipl sclerosi patient walk impair
ahead expect top-lin data second half maintain outperform rate share adama
wb incom william blair compani estim exhibit inc estim revis dollar million except ep stock price capit millionoutperformadama inc william blair
monitor on-going script growth throughout manag commit educ clinician benefit
gocovri gener amantadin key prioriti
question manag
ensur patient remain compliant initi phase gocovri therapi ensur retent script
volum patient retent improv educ initi proce
mean commun clinic evid gocovri evid patient clinician
payer alik earli metric look evalu effect educ program
enrol time frame epilepsi studi expect fda comfort multidos
studi compris pivot data regulatori file
ahead fourth-quart earn estim belbuca product revenu quarter million
quarter-over-quart believ achiev beatabl given prescript growth accord
bloomberg symphoni count third quarter expect prescript growth modestli outpac product
revenu growth estim gross-to-net due discount natur exclus formulari contract
expect dampen quarterli revenu growth franchis total revenu number million
consensu million primarili driven increas belbuca expect impress script growth trajectori
quarter bottom line continu expect loss line consensu exhibit continu
believ investor larg look beyond compani ep long result larg line expect
believ focu continu growth belbuca traction gain recent increas compani
salesforc formulari posit effort improv access belbuca
continu see valu belbuca chronic pain solut amid opioid crisi view recent opioid
legisl impact belbuca prescrib view continu focu opioid crisi tailwind
compani given belbuca less addict reduc abus profil versu mani extend releas opioid expect
continu growth near term manag care contract cover million commerci live kick first
week novemb manag believ growth driven addit prefer contract deeper
penetr manag care plan alreadi prefer statu maintain outperform rate share
biodeliveri scienc continu view belbuca signific growth driver compani earli stage
relaunch manag aim grow million yearli revenu franchis time
question manag
updat regard commerci payer belbuca
see prescript growth benefit salesforc expans versu new payer contract
latest thought timelin profit near-term gross-to-net trend time transform
belbuca million yearli revenu product
absenc purdu pharma market lead tailwind market effort
earli januari collegium manag provid financi guidanc xtampza extended-releas er nucynta
revenu alongsid oper expens adjust model accordingli see note guidanc taper xtampza
er nucynta expect prior contract season take effect reiter outperform slightli tweak
fourth-quart xtampza extended-releas er estim base quarterli script volum report bloomberg
symphoni fourth-quart script count rose quarter-over-quart estim million
revenu exhibit compar consensu million expect script volum ramp first quarter
given janurari execut oxycodon exclus formulari contract cover xtampza er addit
million live xtampza er franchis expect follow trend signific growth phase first half
driven implement new exclus formulari contract forc er-er oxycodon switch follow
moder growth third fourth quarter therapi grow organ oxycontin immediate-releas ir
switch market continu project script growth first quarter exclus formulari contract
take effect moder outer quarter nucynta estim remain unchang million
line consensu product revenu estim fall within manag guidanc issu earlier month
bottom line anticip fourth-quart gaap-report net loss million per share compar
consensu net loss million per share
although renegoti nucynta royalti commit remov guarante million liabil stabil
potenti accret franchis continu work progress despit concern still like stock
see lift exclus contract recent effect expect script growth xtampza er
repeat trend led signific strength share continu believ xtampza er offer signific
growth due statu best-in-class abuse-deterr opioid view product solut contributor
opioid crisi maintain outperform rate
question manag
expect addit win medicar part contract took effect last year hospit formulari
provid prior author oxycontin would win accret xtampza er guidanc
wb incom william blair compani estim exhibit scienc intern inc estim revis dollar million except ep stock price capit millionoutperformcollegium inc william blair
key attribut potenti product acquisit pain space collegium
propos stabil nucynta declin transit assertio expans er sale
abl off-set expect declin ir margin benefici potenti product mix
maintain fourth-quart out-year estim project total revenu
million top line slightli consensu million specif project fourth-quart product
sale million royalti incom million note consensu product sale million
royalti expect million respect anticip investor focus on-going market penetr
big bag ml bendamustin formul bendeka current hold close full market share market
penetr achiev big bag would result proport eros bendeka sale thu compani royalti stream
teva teva project market penetr big bag fourth quarter rise estim peak
penetr rate bottom line fourth-quart non-gaap net incom estim
million per share remain slightli consensu million per share
compani confer call expect focu larg frame commerci expect
particularli regard on-going launch big bag correspond eros bendeka market share also expect
manag comment on-going litig proceed grant orphan drug exclus fda possibl
remov regulatori file current tent approv lyophil powder formul treanda would
compet bendeka end decemb expect manag provid updat use
ryanodex nerv agent toxic develop conjunct militari comment preclin
studi data acut radiat syndrom manag like also comment statu accept anda
file vasopressin inject confirm first file confer day exclus
million market despit signific pipelin setback ryanodex fulvestr pemetrex take confid
strong balanc sheet board-approv share buy-back program maintain outperform rate see sever
option long-term growth irrespect recent disappoint
question manag
wb incom william blair compani estim exhibit inc estim revis dollar million except ep stock price capit millionoutperformeagl inc william blair
expect fda take action delist tent approv lyophil powder
formul treanda major move part make decis
best regulatori path forward ryanodex eh seven addit patient actual meaning
fda given prior
expect next updat regard pemetrex litig anticip addit legal stay
investor event januari portola announc compani expand number hospit stock
andexxa roughli hospit stock third quarter call earli novemb addit
hospit re-ord andexxa signifi complet intern review process support use therapi
see exhibit assum hospit stock averag two dose andexxa per dose would
million sale stock hospit alon addit roughli hospit note re-ord
andexxa third-quart call number grew hospit end year ad addit sale
throughout quarter time hospit begin reorder unknown make estim potenti
sale difficult even conserv assum averag hospit reorder throughout quarter one patient
treat per month well publish util rate two lead center low dose would addit
million sale conserv estim yield combin sale million quarter line current
consensu estim therefor believ greater util averag number hospit reorder
quarter would result sale consensu exampl hospit averag patient per month would result
roughli million sale activ hospit
topic manag
metric commerci launch andexxa includ stock hospit activ order hospit
potenti stock wholesal distributor first quarter
commerci plan europ potenti way bring nondilut capit
end phase ii meet fda discuss next step cerdulatinib compani plan develop
intern seek partner
ahead compani report complet fourth quarter financi result updat estim retrophin
base manag preannounc collect base busi thiola cholbam chenod revenu earli januari
recent adjust estim prior pre-announc henc adjust top-lin revenu estim
million slightli consensu expect million see note rein base busi estim still
expect transform fort studi readout bottom line estim quarterli
net-loss million per share wider consensu estim net loss million per
expect commentari call less focus base-busi metric consid pre-announce
clinic execut four main develop program ahead transform compani
specif expect top-lin data phase ii proof-of-concept trial phenylketonuria pku
patient first half ahead acquisit decis asset first phase readout
compani deep pipelin pivot data subject phase fort trial evalu fosmetpantoten efficaci
treatment pantothen kinase-associ neurodegener pkan on-going updat compani phase
protect trial sparsentan iga nephropathi igan initi decemb updat enrol
compani phase duplex studi sparsentan develop treatment focal segment glomerulosclerosi
fsg patient interim data potenti set compani acceler approv file second half
potenti commerci patient-friendli re-formul thiola year-end nda
submit third quarter also opportun investor hear newli appoint ceo eric
dube ph vision compani throughout transform period remain one favorit
portola manag commentari william blair estimatesexhibit pharmaceuticalsandexxa avail hospit unit hospitalsact stock activ hospitalsstock price capit millionoutperformretrophin inc william blair
name coverag compani well posit ahead multipl clinic readout one largest
pipelin among compani small-cap biotech peer-group
question manag
key clinic data readout pku trial trigger acquisit asset
indic outsid pku could posit
go posit patient-friendli thiola formul market approv year-end
expect accret sale top-lin revenu product patient switch old formul
rational behind earli week egfr readout igan patient enrol protect compar
week fsg patient enrol duplex relat igan patient present less sever
proteinuria thu may see earlier benefit kidney function sparsentan
wb acid incom william blair compani estim exhibit inc estim revis dollar million except ep william blair
follow page append earn model compani coverag univers highlight
report present order list
ticker quarterli financi result projectionsin million except per share dataincom humira hcv imbruvica total product product product in-process research total oper interest expens net foreign exchang incom expens pre-tax incom tax tax net asset separ costs- mileston acquir acquisit relat intang asset tax reform repatri impact relat tax law tax audit legal restructuring- chang fair valu conting transact charit contributions- collaboration- dividend per common averag share outstand katherin xu ph william blair william blair
allergan plc tim lugoearn million except per-shar brand product brand product anda revenues/discont total revenu exclud anda growth total adjust good good oper expens adjust adjust adjust total oper total oper expens incl adjust oper oper interest interest incom non-operating incom expens adjust earn earn adjust provis provis tax net loss continu oper net incom loss discontinu oper net loss incom attribut non-controlling dividend prefer net incom net incom non- perform net incom per ep weight averag share non- weight averag share weight averag share weight averag share percent product sale adjustedadj gross oper net tax percent product sale gross growth adj gross oper net ep ep william blair
inc compani rate market performincom statement dollar million except ep share partner revenu royalti expensescost good gener cost incom incom incom incom attribut incom per shareep gross incom total total growth revenuesq/q incomeq/q consid report singl factor make invest decis sourc report william blair blair affili seek busi compani cover research report result investor awar firm may conflict interest could affect object report william blair
inc compani rate outperformincom statement dollar million except ep share product expensescost good gener cost incom expens incom incom incom attribut incom per shareep gross incom total total growth salesq/q revenuesq/q investor consid report singl factor make invest decis sourc report william blair blair affili seek busi compani cover research report result investor awar firm may conflict interest could affect object report william blair
tim lugobiomarin pharmaceut inc william blair companyoutperform statement million except per share salesaldurazym net product product agreement enues- royalti licens revenues/vouch exchang effect- total yr/yr servic good intang impair intang assets- sale intang asset- total oper expens incom loss incom biomarin/genzym incom loss interest interest impair loss investment- sale investments- debt convers expense- incom loss tax provis incom net incom net incom net loss per share dilut loss per share dilut product salestot gross margin gross william blair
bristol-my squibbcompani rate outperformincom statement dollar million except ep share product expensescost good sell incom incom incom attribut incom per shareep gross incom total total growth salesq/q revenuesq/q consid report singl factor make invest decis sourc bristol-my report william blair blair affili seek busi compani cover research report result investor awar firm may conflict interest could affect object report william blair
inc ticker quarterli financi result projectionsin million except per share inc incom net hcv product royalti contract total sg total oper interest expens incom expens pre-tax provis incom net incom loss attribut non-controlling net incom attribut reconciliationcost good sold expens sg expens interest expens total non-gaap adjust incom tax effect tax reform total non-gaap adjust non-gaap net incom attribut dividend per common averag share outstand katherin xu ph william blair william blair
incyquarterli result thousand except per share data corporationincom jakavi royalti royalti iclusig eu contract total product sg chang fair valu acquisition-rel conting expenses- total oper oper interest incom interest debt exchang expens senior note unreal loss long term invest loss repurchase/redempt convert senior subordin total incom pre-tax comprehens gain/ loss provis incom net reconciliationmileston revenu new exist up-front consider mileston relat non-cash stock comp equiti asset impair in-process chang fair valu conting amort acquir product chang fair valu equiti non-cash interest exp relat conv expens relat senior note tax effect non-gaap total non-gaap non-gaap net non-gaap ep ep averag share outstand weight averag share outstand katherin xu ph william blair compani william blair
inc ticker inc quarterli result thousand except per share inc incom world-wide combo incl orkambi orkambi world-wide symdeko world-wide cf tripl combo world-wide sales- hcv net royalti collabor total restructur expens intang asset impair acquisit relat expense- total oper interest exchang convert notes- incom pre-tax incom effect tax incom loss attribut non-controlling net incom loss atribut vertex non-gaap incom stock-bas compensation- stock-bas compens stock-bas compens transaction/hcv-rel costs- septemb transactions- intang asset impair charg net tax- collabor transact revenu expenses- restructur non-oper tax adjustments- one-tim total averag share outstand averag share outstand adj adj expensesi katherin xu ph william blair william blair
inc compani rate outperformincom statement dollar thousand except ep share oper incom expens interest incom extinguish incom incom incom per share ave share ave share report william blair compani william blair
sarepta inc tim lugotick result million except per share golodirsen- casimersen- total sg acquir in-process intang asset impair charge- litig licens amort in-licens rights- total oper oper interest loss chang warrant valuation- sale intang realiz gain sale short-term securities- write short-term secur availbl sale- pre-tax net incom loss gain attribut non-controlling interest alio provis incom net incom net incom ep averag share outstand william blair
rate outperformaclari inc tim lugoearn enueseskata seborrh keratoses- rhofad rosacea erythema- w/w common warts- total product enue- servic enue- total yr/yr good gross oper expens incl cog oper incom growth y/i incom expens net- incom expens incom tax effect tax rate incom loss per share fulli basic dilut weight average share common ratio unless note gross total total marginnananananananananet incom marginnanananananananaenu growthgrowth growthgrowth growthgrowth growthgrowth yr/yrnanananananananagrowth thousand except ep data william blair
rate outperformadama pharmaceuticalstim lugoearn revenue- gocovri royalty/mileston total yr/yr good gross yr/yr yr/yr oper expens excl yr/yr ebit growth y/i incom interest expens incl royalti incom tax effect tax rate net incom common per share net incom common per share basic average number share use comput net dilut average number share use comput net thousand except ep data william blair
biodeliveri sciencesr outperformearn modeltim enuebunavail clonidin topic gel- belbuca research contract total product parti net- total expens interest deriv loss gain- bargain purchas gainoth expens incom loss incom incom tax effect tax rate incom tax ep ep share share ratio unless note gross total total incom growthgrowth growthgrowth growth non- growth yr/yrnmnmnmnmnmnmnmnmgrowth thousand except ep data william blair
rate outperformcollegium pharmaceut inc tim lugoearn enuextampza pipelin productstot product royalti payment total product gross yr/yr yr/yr expens oper interest incom gain mileston payments- expens incom loss incom incom tax provision- effect tax rate incom tax ep ep share ratio unless note gross total total incom growthgrowth growthgrowth yr/yrn/an/an/an/an/an/an/an/agrowth q/qn/an/an/an/an/an/an/an/aep growth non- growth yr/yrnmnmnmnmnmnmnmnmgrowth thousand except ep data william blair
lugoearn royalti licens total yr/yr revenue q/qtotal gross product sale non- total oper expens includ incom ebit margin growth y/i ebitda margin interest interest total net incom tax incom tax benefit provis effect tax/ benefit rate incom net incom dilut net incom per common dilut net incom per common share dilut share common ratio unless note gross total total incom growthgrowth growthgrowth growthgrowth growth growth rate switch non- thousand except ep data william blair
inc compani rate outperformincom statement dollar thousand except ep share licens oper incom income/loss incom tax expens income/loss per common share averag number share blair affili seek busi compani cover research report result investor awar firm may conflict interest could affect object report investor consid report singl factor make invest decis sourc portola report william blair william blair
inc rate outperformearn modeltim product bile acid pipelin productsl-udca- sparsentan- fosmetpantoten total yr/yr good gross growthnon-gaap growthnon-gaap growthother/ chang fair valu conting total oper expens non-gaap total oper expens oper growth y/i non-gaap oper growth y/i depreci gain sale assets- litig settlement gain- interest incom expens financ expense- earli payment penalty- registr payment oblig net- realiz gain sale market secur net- chang fair valu deriv financi gain loss transact denomin foreign currencies- purchas gain- incom total expens incom tax incom tax net incom non-gaap net incom gaap net incom loss per share non-gaap net incom loss per share basic weight average share common thousand except ep data import disclosur
